HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

NIH, CDC Distributing OTC COVID-19 Tests In US Study On Reducing Community Transmission

Executive Summary

NIH pays for 2m of Quidel's QuickVue tests in a program it’s conducting with CDC to determine whether frequent self-administered testing helps reduce community transmission of SARS-CoV-2.

You may also be interested in...



Abbott, BD, Quidel OTC COVID-19 Tests Granted Emergency Use Authorization In US

FDA grants emergency use authorization to OTC COVID-19 testing products as it targets allowing workplaces, schools and communities to access tools needed to screen for the virus rapidly and accurately.

US FDA Recommendations On Developing Serial COVID-19 Tests Could Accelerate OTC Approval

FDA published a supplemental template for molecular and antigen COVID-19 EUA sponsors with products to be used for serial testing, and a fact sheet that screening program organizers can use to pick the right test.

California Bill To Age-Restrict Sales Of Diet Pills Further Along Than Other States’ Legislation

CA, MA and NJ legislatures remain in session with bills active proposing regulations similar to NY law effective 22 April requiring retailers, including online, to ask for proof of age when customers buying consumer health products containing ingredients labeled or promoted for weight loss and bodybuilding benefits appear younger than 18.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

RS151198

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel